Personal information

No personal information available

Activities

Collapse all

Employment (5)

University of Medicine and Pharmacy of Craiova: Craiova, RO

2021-10-01 to present | Head of (Oncology)
Employment
Source: Self-asserted source
Michael Schenker

University of Medicine and Pharmacy of Craiova: Craiova, RO

2019-09-01 to present | Associate Professor (Oncology)
Employment
Source: Self-asserted source
Michael Schenker

Centrul de Oncologie Sf Nectarie Craiova: Craiova, Dolj, RO

2014-01-01 to present | Medical Director (Medical Oncology)
Employment
Source: Self-asserted source
Michael Schenker

University of Medicine and Pharmacy of Craiova: Craiova, RO

2012-07-01 to 2019-08-31 | Lecturer (Oncology)
Employment
Source: Self-asserted source
Michael Schenker

University of Medicine and Pharmacy of Craiova: Craiova, RO

2002-10-01 to 2012-06-30 | Assistant Professor (Oncology)
Employment
Source: Self-asserted source
Michael Schenker

Works (16)

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

Journal of Clinical Oncology
2025-01 | Journal article
DOI: 10.1200/JCO.24.00340
Contributors: Matthew D. Galsky; Johannes Alfred Witjes; Jürgen E. Gschwend; Matthew I. Milowsky; Michael Schenker; Begoña P. Valderrama; Yoshihiko Tomita; Aristotelis Bamias; Thierry Lebret; Shahrokh F. Shariat et al.
Source: check_circle
Crossref

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238

Journal of Clinical Oncology
2024-11 | Journal article
DOI: 10.1200/JCO.23.01448
Contributors: Jeffrey Weber; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance; Stephane Dalle; C. Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Data from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6637744.v3
Contributors: James Larkin; Michele Del Vecchio; Mario Mandala; Helen Gogas; Ana M. Arance; Stephane Dalle; Charles Lance. Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Data from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6637744
Contributors: James Larkin; Michele Del Vecchio; Mario Mandala; Helen Gogas; Ana M. Arance; Stephane Dalle; Charles Lance. Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27030961.v1
Contributors: James Larkin; Michele Del Vecchio; Mario Mandala; Helen Gogas; Ana M. Arance; Stephane Dalle; Charles Lance. Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27030961
Contributors: James Larkin; Michele Del Vecchio; Mario Mandala; Helen Gogas; Ana M. Arance; Stephane Dalle; Charles Lance. Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

ESMO Open
2024-03 | Journal article
DOI: 10.1016/j.esmoop.2024.102387
Contributors: A.M. Di Giacomo; M. Schenker; J. Medioni; S. Mandziuk; M. Majem; G. Gravis; M. Cornfeld; S. Ranganathan; S. Lou; T. Csoszi
Source: check_circle
Crossref

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Clinical Cancer Research
2023-09-01 | Journal article
DOI: 10.1158/1078-0432.CCR-22-3145
Contributors: James Larkin; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance Fernandez; Stéphane Dalle; Charles Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Data from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

2023-09-01 | Preprint
DOI: 10.1158/1078-0432.c.6637744.v2
Contributors: James Larkin; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance Fernandez; Stéphane Dalle; Charles Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

2023-09-01 | Preprint
DOI: 10.1158/1078-0432.24071561
Contributors: James Larkin; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance Fernandez; Stéphane Dalle; Charles Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

2023-09-01 | Preprint
DOI: 10.1158/1078-0432.24071561.v1
Contributors: James Larkin; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance Fernandez; Stéphane Dalle; Charles Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Data from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

2023-05-09 | Preprint
DOI: 10.1158/1078-0432.c.6637744.v1
Contributors: James Larkin; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance Fernandez; Stéphane Dalle; Charles Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

2023-05-09 | Preprint
DOI: 10.1158/1078-0432.22787545.v1
Contributors: James Larkin; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance Fernandez; Stéphane Dalle; Charles Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

2023-05-09 | Preprint
DOI: 10.1158/1078-0432.22787545
Contributors: James Larkin; Michele Del Vecchio; Mario Mandalá; Helen Gogas; Ana M. Arance Fernandez; Stéphane Dalle; Charles Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Journal of Clinical Oncology
2023-01-20 | Journal article
DOI: 10.1200/JCO.22.00533
Contributors: Jeffrey S. Weber; Dirk Schadendorf; Michele Del Vecchio; James Larkin; Victoria Atkinson; Michael Schenker; Jacopo Pigozzo; Helen Gogas; Stéphane Dalle; Nicolas Meyer et al.
Source: check_circle
Crossref

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

European Journal of Cancer
2022-09 | Journal article
DOI: 10.1016/j.ejca.2022.06.041
Contributors: James Larkin; Jeffrey Weber; Michele Del Vecchio; Helen Gogas; Ana M. Arance; Stephane Dalle; C. Lance Cowey; Michael Schenker; Jean-Jacques Grob; Vanna Chiarion-Sileni et al.
Source: check_circle
Crossref
How many people are using ORCID?